Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study

Eric Lawitz, Mark S. Sulkowski, Reem Ghalib, Maribel Rodriguez-Torres, Zobair M. Younossi, Ana Corregidor, Edwin Dejesus, Brian Pearlman, Mordechai Rabinovitz, Norman Gitlin, Joseph K. Lim, Paul J. Pockros, John D. Scott, Bart Fevery, Tom Lambrecht, Sivi Ouwerkerk-Mahadevan, Katleen Callewaert, William T. Symonds, Gaston Picchio, Karen L. LindsayMaria Beumont, Ira M. Jacobson

Research output: Contribution to journalArticlepeer-review

621 Scopus citations

Fingerprint Dive into the research topics of 'Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study'. Together they form a unique fingerprint.

Medicine & Life Sciences